Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.47 |
| ▸ | PNMT | P11086 | 3/20 | 0.44 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6685097 | 0.87 | RIPK1 (0.56) | RIPK1TAAR1SLC6A2ESR1 | |
| SCHEMBL28293880 | 0.84 | TAAR1 (0.52) | RIPK1PNMTDPP4TAAR1SLC6A2 | |
| SCHEMBL9718549 | 0.80 | RIPK1 (0.50) | RIPK1TAAR1SLC6A2ESR1 | |
| Methylamine SCHEMBL28339099 | 0.79 | PNMT (0.57) | PNMTDPP4TAAR1SLC6A2LOXL2 | |
| SCHEMBL15247 | 0.79 | PNMT (0.63) | PNMTDPP4TAAR1LOXL2 | |
| SCHEMBL29405036 | 0.79 | PNMT (0.63) | PNMTDPP4TAAR1LOXL2 | |
| SCHEMBL18325596 | 0.79 | DPP4 (0.41) | RIPK1PNMTDPP4TAAR1SLC6A2 | |
| SCHEMBL6685032 | 0.78 | RIPK1 (0.48) | RIPK1TAAR1SLC6A2ESR1 | |
| SCHEMBL27794513 | 0.77 | PNMT (0.38) | RIPK1PNMTDPP4TAAR1SLC6A2 | |
| SCHEMBL358741 | 0.76 | RIPK1 (0.47) | RIPK1TAAR1SLC6A2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002251-A1 | HUMAN TLR8-SELECTIVE AGONISTS | UNIVERSITY OF KANSAS (US) | 2022-01-06 | — | — | US | disclosed |
| US-11130736-B2 | Human TLR8-selective agonists | UNIVERSITY OF KANSAS (US) | 2021-09-28 | — | — | US | disclosed |
| US-9695260-B2 | Method for producing olefin block polymer using plurality of types of transition metal catalysts | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9593194-B2 | Method for producing olefin block polymer using group 4 transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-03-14 | — | — | US | disclosed |
| US-20160009733-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | UNIVERSITY OF WOLLONGONG (AU) | 2016-01-14 | — | — | US | disclosed |
| US-9156855-B2 | Regulation of nitric oxide release and biofilm development | Newsouth Innovation Pty Limited (AU) | 2015-10-13 | — | — | US | disclosed |
| US-8871885-B2 | Ethylene-a-olefin copolymer and molded article | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-10-28 | — | — | US | disclosed |
| US-20140275429-A1 | METHOD FOR PRODUCING OLEFIN BLOCK POLYMER USING PLURALITY OF TYPES OF TRANSITION METAL CATALYSTS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-09-18 | — | — | US | disclosed |
| US-8809462-B2 | Ethylene-α-olefin copolymer, molded article, catalyst for copolymerization, and method for producing an ethylene-α-olefin copolymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20140221331-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | UNIVERSITY OF WOLLONGONG (AU) | 2014-08-07 | — | — | US | disclosed |
| US-20040209767-A1 | Contact product, and catalyst component and catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-10-21 | — | — | US | disclosed |
| US-20040186009-A1 | Catalyst component and catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-09-23 | — | — | US | disclosed |
| US-20030203810-A1 | Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-10-30 | — | — | US | disclosed |
| US-6586356-B2 | Coordination catalyst | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-07-01 | — | — | US | disclosed |
| US-20030069127-A1 | Modified particle,support, catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMTED (JP) | 2003-04-10 | — | — | US | disclosed |
| EP-1300425-A2 | Catalyst component for addition polymerization, process for producing said catalyst and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-20030060579-A1 | Catalyst component for addition polymerization, process for producing catalyst for addition polymerization and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-27 | — | — | US | disclosed |
| US-20020143124-A1 | Homogeneous type solid catalyst component or homogeneous type solid catalyst, process for production thereof and process for producing addition polymer with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-10-03 | — | — | US | disclosed |
| US-20010020075-A1 | Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-09-06 | — | — | US | disclosed |
| EP-1113026-A2 | Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130736-B2 | Human TLR8-selective agonists | TLR7, TLR8, TLR9 | RIPK1 953/4885PNMT 4710/4885DPP4 2641/4885 |
| US-20160009733-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | NOS1, NOS2, NOS3 | RIPK1 404/4885PNMT 991/4885DPP4 3018/4885 |
| US-20140221331-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | NOS1, NOS2, NOS3 | RIPK1 404/4885PNMT 991/4885DPP4 3018/4885 |
| US-20220002251-A1 | HUMAN TLR8-SELECTIVE AGONISTS | TLR7, TLR8, TLR9 | RIPK1 953/4885PNMT 4710/4885DPP4 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.